Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00051506 · ClinicalTrials.gov registry record · Phase 2

ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.

A Phase 2 study, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 2
Development phase

NCT00051506 is a Phase 2 study that has completed, run by Eli Lilly and Company.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00051506, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 2
Development phase

Study Summary

The purpose of this study is to evaluate the effects (good and bad) of ALIMTA plus Carboplatin or ALIMTA plus Cisplatin on you and your small cell lung cancer.

Interventions

  • DRUG cisplatin
  • DRUG carboplatin
  • DRUG ALIMTA

Trial Details

FieldValue
Phase Phase 2

Sponsor

Eli Lilly and Company

1,341 total trials

What the Registry Record Tells You About NCT00051506

The ClinicalTrials.gov registry entry for NCT00051506 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.

NCT00051506 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00051506 about?

NCT00051506 is a clinical study titled "ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.". The purpose of this study is to evaluate the effects (good and bad) of ALIMTA plus Carboplatin or ALIMTA plus Cisplatin on you and your small cell lung cancer.

What is the current status of trial NCT00051506?

This trial is currently completed. It is a Phase 2 study.

What interventions are being tested in trial NCT00051506?

The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), ALIMTA (DRUG).

Who is sponsoring clinical trial NCT00051506?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.